在原始B细胞中的TCL1A作为1型糖尿病的治疗点
Siweier Luo1, Lina Zhang2, Chunfang Wei3
1Department of Paediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510120, China; Basic and Translational Medical Research Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510120, China; Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510120, China.
研究人员在早期1型糖尿病 (T1D) 中发现了表达TCL1A的B细胞增加. 用纳米药物向TCL1A减少了这些细胞,保护了胰腺细胞,并改善了小鼠的葡萄糖不耐受性,提供了一个新的T1D治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 1型糖尿病 (T1D) 是一种针对胰腺β细胞的自身免疫性疾病.
- 特定的B细胞群在T1D早期发病过程中的作用尚不清楚.
- 乙细胞通过抗原呈现和自身抗体的产生为T1D作出贡献.
研究的目的:
- 在1型糖尿病中研究早期B细胞种群.
- 确定T1D免疫治疗的分子标.
- 评估针对B细胞自身免疫的治疗潜力.
主要方法:
- 在T1D患者和对照组中进行单细胞RNA测序 (scRNA-seq) 和流细胞计.
- 对B细胞的蛋白微阵列分析.
- 在NOD小鼠中开发和测试基于siRNA的纳米医学.
主要成果:
- 在早期T1D患者和NOD小鼠中观察到表达TCL1A的原始B细胞增加.
- TCL1A knockdown 损害了 AKT2 酸化,影响了 B 细胞的存活和增殖.
- 针对Tcl1amRNA的纳米药物减少了天真B细胞,保留了β细胞,并在T1D小鼠中改善了葡萄糖耐受性.
结论:
- 表达TCL1A的原始B细胞与1型糖尿病的发病有关.
- 针对TCL1A的基于siRNA的纳米医学显示了T1D的治疗潜力.
- 这些发现的临床转化可以提供新的T1D治疗策略.
相关概念视频
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...


